Comparison of LACE and HOSPITAL Readmission Risk Scores for CMS Target and Nontarget Conditions.

Autor:	Jones SL; Center for Outcomes Research, Houston Methodist, Houston, TX.; Department of Surgery, Houston Methodist, Houston, TX.; Department of Surgery, Weill Cornell Medical College, New York, NY., Cheon O; Center for Outcomes Research, Houston Methodist, Houston, TX.; Reh School of Business, Clarkson University, Schenectady, NY., Manzano JM; Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Park AK; Office of Performance Improvement, The University of Texas MD Anderson Cancer Center, Houston, TX., Lin HY; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Halm JK; Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Baek J; Center for Outcomes Research, Houston Methodist, Houston, TX., Graviss EA; Department of Surgery, Houston Methodist, Houston, TX.; Department of Pathology and Genomic Medicine, Houston Methodist, Houston, TX.; Houston Methodist Hospital Research Institute, Houston Methodist, Houston, TX., Nguyen DT; Department of Pathology and Genomic Medicine, Houston Methodist, Houston, TX.; Houston Methodist Hospital Research Institute, Houston Methodist, Houston, TX., Kash BA; Center for Outcomes Research, Houston Methodist, Houston, TX.; School of Public Health, Texas A&M University, College Station, TX., Phillips RA; Center for Outcomes Research, Houston Methodist, Houston, TX.; Department of Medicine, Weill Cornell Medical College, New York, NY.
Jazyk:	angličtina
Zdroj:	American journal of medical quality : the official journal of the American College of Medical Quality [Am J Med Qual] 2022 Jul-Aug 01; Vol. 37 (4), pp. 299-306. Date of Electronic Publication: 2021 Dec 20.
DOI:	10.1097/JMQ.0000000000000035
Abstrakt:	This study evaluated the utility and performance of the LACE index and HOSPITAL score with consideration of the type of diagnoses and assessed the accuracy of these models for predicting readmission risks in patient cohorts from 2 large academic medical centers. Admissions to 2 hospitals from 2011 to 2015, derived from the Vizient Clinical Data Base and regional health information exchange, were included in this study (291 886 encounters). Models were assessed using Bayesian information criterion and area under the receiver operating characteristic curve. They were compared in CMS diagnosis-based cohorts and in 2 non-CMS cancer diagnosis-based cohorts. Overall, both models for readmission risk performed well, with LACE performing slightly better (area under the receiver operating characteristic curve 0.73 versus 0.69; P ≤ 0.001). HOSPITAL consistently outperformed LACE among 4 CMS target diagnoses, lung cancer, and colon cancer. Both LACE and HOSPITAL predict readmission risks well in the overall population, but performance varies by salient, diagnosis-based risk factors. (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American College of Medical Quality.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu